Search Results for "vaccine, adult"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, adult. Results 91 to 100 of 293 total matches.
See also: MMR II
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2024-2025
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024 (Issue 1711)
and pericarditis
after receipt of COVID-19 vaccines among adolescents and
young adults. October 10, 2023 ...
New 2024-2025 formulations of the mRNA COVID-19
vaccines manufactured by Pfizer/BioNTech (Comirnaty)
and Moderna (Spikevax) that more closely target
currently circulating variants have been licensed by
the FDA for persons ≥12 years old and made available
under FDA Emergency Use Authorizations (EUAs) for
use in persons 6 months to 11 years old.1-3 A 2024-2025
formulation of the adjuvanted protein subunit COVID-19
vaccine manufactured by Novavax is expected to
become available soon for persons ≥12 years old.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):151-2 doi:10.58347/tml.2024.1711c | Show Introduction Hide Introduction
BioThrax and Anthrasil for Anthrax
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
immune globulin
(Anthrasil – Emergent BioSolutions) for treatment of
inhalation anthrax in adults ...
The FDA has approved anthrax vaccine adsorbed (AVA;
BioThrax – Emergent BioSolutions) for prevention of
anthrax disease in adults following exposure to Bacillus
anthracis and intravenous anthrax immune globulin
(Anthrasil – Emergent BioSolutions) for treatment of
inhalation anthrax in adults and children. AVA has been
available since 1970 for prevention of anthrax disease
in persons at high risk of exposure.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
trial in 562 nonhospitalized,
SARS-CoV-2-positive adults who had developed
symptoms of COVID-19 ≤7 ...
The IV antiviral drug remdesivir (Veklury – Gilead)
has been available for treatment of COVID-19 in
hospitalized patients since 2020. Now, the FDA has
approved remdesivir for treatment of mild to moderate
COVID-19 in outpatients ≥12 years old who weigh
≥40 kg and are at high risk for progression to severe
disease, including hospitalization or death; they
also issued an Emergency Use Authorization (EUA)
allowing its use in any other high-risk outpatient who
weighs ≥3.5 kg.
Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
-policy.
2. Approved for use in adults.
3. For patients switching from immune globulin intravenous (IGIV ...
The FDA has approved a subcutaneously administered
20% solution of human immune globulin (Cuvitru –
Shire) for replacement therapy in patients ≥2 years old
with a primary humoral immunodeficiency. Hizentra
(CSL Behring), another subcutaneously administered
20% immune globulin solution, was approved in 2010
for the same indication. The IgG component of Cuvitru
is similar to that of Gammagard Liquid and HyQvia, two
subcutaneously administered 10% immune globulin
formulations also manufactured by Shire and approved
for treatment of primary...
Mumps Outbreak
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014 (Issue 1438)
in the US
have occurred predominantly in vaccinated older teenagers
and young adults who are ≥10 years past their last ...
An outbreak of mumps has occurred among students at
Fordham University in New York. All of those who developed
mumps had been vaccinated against the disease.
COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
are not authorized for primary
immunization against COVID-19. The monovalent
Pfizer and Moderna COVID-19 vaccines ...
The FDA has expanded its Emergency Use
Authorizations (EUAs) for the COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) to permit use of the bivalent
formulations of these products (containing mRNA
from the original and BA.4/5 Omicron strains of
SARS-CoV-2) as a booster dose in children as young
as 5 years old (Pfizer) or 6 years old (Moderna).
The bivalent Pfizer vaccine had previously been
authorized for use in persons ≥12 years old and the
bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old ...
On May 10, 2021, the FDA expanded its Emergency
Use Authorization (EUA) for the Pfizer/BioNTech
mRNA-based COVID-19 vaccine to include adolescents
12-15 years old.1The vaccine has been
authorized for use in persons ≥16 years old since
December 2020.
Rimantadine for Prevention and Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • Nov 26, 1993 (Issue 910)
in the vaccine, or if vaccine is
unlikely to produce an adequate immune response, as in patients ...
Rimantadine hydrochloride (Flumadine - Forest), the alpha-methyl derivative of amantadine (Symmetrel, and others), was recently approved by the US Food and Drug Administration for prevention and treatment of influenza A virus infections in adults and for prevention of influenza in children.
COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (Online Only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
vaccine are
not currently eligible for booster immunization.1,4
The CDC recommends that children 6 ...
The FDA has expanded its Emergency Use
Authorizations (EUAs) for the COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) to permit use of the bivalent
formulations of these products (containing mRNA
from the original and BA.4/5 Omicron strains of
SARS-CoV-2) in children as young as 6 months.
The bivalent Pfizer vaccine is authorized for use as
the final dose of a 3-dose primary series in children
6 months to 4 years old. The bivalent Moderna
vaccine is authorized for use as a booster dose in
children 6 months to 5 years old who completed
a primary...
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022 (Issue 1648)
booster vaccine and Covid-19 mortality
in adults 60 to 100 years old. Research Square 2022 March 24 ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use as a second
booster dose ≥4 months after a first booster dose in
adults ≥50 years old and in persons aged ≥12 years
(Pfizer) or ≥18 years (Moderna) who have undergone
solid organ transplantation or have a condition that
compromises the immune system to a similar extent.